



Meningococcal Vaccines Session

David S. Stephens, M.D.

Chair, Meningococcal Work Group

Advisory Committee on Immunization Practices

October 19, 2016

Revised Dosing Schedule for MenB-FHbp (Trumenba®)

- Changes to the dosage and administration section for MenB-FHbp approved by FDA on April 14, 2016

- Original language:

Three doses according to a 0, 2, and 6 month schedule

- Updated language:

Three-dose schedule: Administer a dose at 0, 1-2, and 6 months

Two-dose schedule: Administer a dose at 0 and 6 months

The choice and dosing schedule may depend on the risk of exposure and the patient's susceptibility to meningococcal serogroup B disease

Agenda

- Impact of MenB-FHbp (Trumenba) on meningococcal carriage
 - Dr. Heidi Soeters (CDC/NCIRD)
- Immunogenicity studies of two MenB vaccines in adults
 - Dr. Dan Granoff (Children's Hospital Oakland Research Institute)
- MenB-FHbp update
 - Dr. Laura York (Pfizer)
- Considerations for use of 2- and 3-dose schedules of MenB-FHbp
 - Ms. Jessica MacNeil (CDC/NCIRD)
- ACIP and VFC votes anticipated

Policy Options for 2- or 3-Dose Schedules of MenB-FHbp (Trumenba[®])

1. For persons at increased risk and for use during outbreaks:
 - Preference for 3-dose schedule (0, 1-2, 6 months)

2. When given to healthy adolescents:
 - Preference for 2-dose schedule (0, 6 months)
 - OR*
 - Option for 2- (0, 6 months) or 3-dose (0, 1-2, 6 months) schedule
 - OR*
 - Preference for 3-dose schedule (0, 1-2, 6 months)

Additional Work Group Activities

- Policy Note: Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons: Advisory Committee on Immunization Practices, 2016
 - To be published in MMWR on November 4, 2016
- Next steps:
 - Continue to review new data on MenB vaccines as it becomes available
 - Consider booster doses of MenB vaccine for persons at increased risk

Work Group Members

ACIP Members

- David Stephens (Chair)
- Kelly Moore

Ex Officio Members

- Lucia Lee (FDA)
- Anuja Rastogi (FDA)
- Margaret Yacovone (DOD)

CDC Work Group Lead

- Jessica MacNeil (CDC/NCIRD)

Liaison Representatives

- Carol Baker (IDSA)
- Susan Even (ACHA)
- Rachel Herlihy (IAC)
- Nneka Holder (SAHM)
- Martin Luta (CSTE)
- Ruth Lynfield (AAP)
- Paul McKinney (APTR)
- Jeffrey Moore (AAFP)
- William Schaffner (NFID)

Consultants

- Bill Atkinson
- Mike Brady
- Doug Campos-Outcalt
- Richard Clover
- Kathleen Harriman
- Lee Harrison
- Mary Healy
- Cody Meissner
- Paul Offit
- Georges Peter
- Lorry Rubin

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

